$BKKT

Alexander Karen sold $6K of BKKT

Alexander Karen (Chief Financial Officer) sold 657 shares of Bakkt, Inc. (BKKT) at $8.44 on 2026-07-15.

Original reporting
SEC EDGAR · Alexander Karen
Published Jul 17, 2026, 5:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 5:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BKKT
Neutral
medium confidence
Mentioned
$BKKT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BKKTNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it may influence short-term sentiment but provides no operational or financial guidance change.

02

Market read

Traders may monitor for follow-on insider activity, but the filing does not introduce a new fundamental catalyst.

03

What to watch

No 10b5-1 plan is stated, but the filing alone does not reveal the reason for sale, whether other tranches exist, or whether options/other grants offset the sale.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date 2026-07-17 for a 2026-07-15 sale

Background

This is an SEC Form 4 insider transaction disclosure for Bakkt, Inc. (BKKT) by its CFO.

Company-level read

Ticker impact

$BKKTNeutralMedium confidence
Context

Bakkt CFO Alexander Karen filed a Form 4 open-market sale of 657 shares at $8.44 on 2026-07-15.

Expected impact

Low likelihood of a sustained price move; any reaction would be limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a small, single-tranche open-market sale by an officer, with no accompanying corporate event, guidance, or operational update in the text.

Market effects

Minimal; insider sales do not typically reset sector expectations without additional company-specific news.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs and does not necessarily signal reduced confidence, especially without any other negative company developments.

Key entities

  • BKKT

    Bakkt, Inc., the company whose CFO insider sale is disclosed on Form 4.

  • Alexander Karen

    Bakkt CFO who sold 657 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BKKTMedAI 8/10

Bakkt (BKKT) Q2 2026 Earnings Call Transcript

Bakkt (BKKT) reported Q2 2026 revenue of $170.1 million, down 70% from $568.1 million, citing client transitions and weaker digital asset trading volumes. GAAP net income was $80.8 million, driven mainly by a $98.5 million non-cash gain from Transchem warrants. Total transacting volume was $168.8 million; management reiterated an EBITDA breakeven target in Q4 2026.

$BKKTMed

Bakkt Inc (BKKT) (Q2 2026) Earnings Call Highlights: Strong GAAP Net Income

Bakkt’s CEO Akshay Naheta said the company expects adjusted EBITDA break-even in Q4 2026, without a specific date, citing execution and client activations. Management discussed take rates, cross-border margins, and reaffirmed a 2026 TTV target of about $2.5 billion. The firm outlined post-DTR acquisition progress and Bakkt Agent MAU target of ~25,000 by year-end 2026.

$BKKTMed

Bakkt, Inc. (BKKT): Results of Operations and Financial Condition

Bakkt, Inc. (BKKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bakkt Reports Second Quarter 2026 Results - GAAP net income of $80.8 million, or $1.96 per basic and $1.94 per diluted share - Six commercial offerings live across Bakkt Markets; Total Transacting Volume (“TTV”) of $168.8 million in Q2, including payments volume generated on acqu